Argenica Therapeutics Ltd has released a press release.
Appendix 4E & Annual Report to 30 June 2024
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- ARG-007 Reduces Effects of TBI in Preclinical Study
- DSMB Confirms Safety of First Patients Dosed
- Argenica Successfully Completes $12.0m Placement
- Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
- First Patient Dosed in Phase 2 Stroke Trial of ARG-007
Later from Argenica Therapeutics
- Positive Results in Key IND Enabling Studies
- FDA Grants ODD & RPDD for Second Drug in Treatment of HIE
- Quarterly Activities/Appendix 4C Cash Flow Report - updated
- $2.76m R&D Tax Incentive Cash Rebate Received for FY24
- Phase 2 Stroke Clinical Trial Update
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics